Secretoneurin and NT-proBNP should be included in the risk assessment of patients being evaluated for cardiac surgery, according to Jon Brynildsen‘s PhD thesis.


MAIN RESULTS:

  1. Measuring NT-proBNP or secretoneurin could improve risk prediction in cardiac surgical patients.
  2. A simple model of NT-proBNP and three easily available clinical risk factors is probably at least as good as EUROSCORE II in predicting long-term outcome after heart surgery.
  3. Secretoneurin also improves risk prediction in aortic stenosis.

THESIS DEFENCE:

Thesis: A search for novel treatments against ventricular arrhythmias
Candidate: Jon Brynildsen
Time: June 25, 2020 at 11:15
Place: Online-based solution, due to the covid-19 situation
Link to university website


SUMMARY:

(1/2) N-terminal pro-B-type natriuretic peptide, (NT-proBNP), secretoneurin and high-sensitivity troponin T (hs-TnT) levels measured pre- and post-operatively are lower in patients that are still alive 2-3 years after cardiac surgery, compared to non-survivors. Moreover, NT-proBNP and postoperative secretoneurin improves risk stratification when added to the commonly used EUROSCORE II model. Including age, creatinine clearance, COPD and NT-proBNP in a single model predicted prognosis comparatively well to EUROSCORE II.

The studies include pre- and postoperative samples from more than 600 cardiac surgical patients. The median follow-up time was 961 days, by which 10% of the patients had died. The predictive ability of NT-proBNP were also confirmed in a cohort of 90 patients with respiratory failure after cardiac surgery.

(3) Secretoneurin adds prognostic information on top of established risk models in patients with moderate to severe aortic stenosis. The study includes 57 patients, of which 15 died during a median of 3.5 years follow-up. Non-survivors had higher levels of secretoneurin, and the association remained after adjustment for established risk indices, biomarkers and surgical status.


REFERENCES:

(1) Brynildsen, J., Petäjä, L., Pettilä, V., Nygård, S., Vaara, S. T., Linko, R., Okkonen, M., Hagve, T.-A., Soininen, L., Suojaranta-Ylinen, R, Lyngbakken, M. N., Omland, T., & Lyngbakken, M. N. (2018). The predictive value of NT-proBNP and hs-TnT for risk of death in cardiac surgical patientsClinical biochemistry53, 65-71.

(2) Brynildsen, J., Petäjä, L., Myhre, P. L., Lyngbakken, M. N., Nygård, S., Stridsberg, M., Christensen, G., Ottesen, A., Pettilä, V., Omland, T., & Røsjø, H. (2019). Circulating Secretoneurin Concentrations After Cardiac Surgery: Data From the FINNish Acute Kidney Injury Heart StudyCritical care medicine47(5), e412-e419.

(3) Brynildsen, J., Myhre, P. L., Lyngbakken, M. N., Klaeboe, L. G., Stridsberg, M., Christensen, G., Edvardsen, T., Omland, T., & Røsjø, H. (2019). Circulating secretoneurin concentrations in patients with moderate to severe aortic stenosis. Clinical biochemistry71, 17-23.

Latest News

May 28, 2024

Photos from the workshop on Advancing Ischemic Heart Disease Research

Approximately 25 researchers met in Trondheim for the new workshop called “Advancing Ischemic Heart Disease…

Read more
May 14, 2024

Photos from Course in Cardiac Mechanics 2024

Cardiac researchers and clinical cardiologists need to know key concepts and terms for measuring and describing…

Read more
April 28, 2024

Professor Kristina H. Haugaa receives the 2024 Heart Research Award

The Norwegian Health Association has awarded the prestigious 2024 Heart Research Award (Hjerteforskningsprisen) to professor Kristina…

Read more
September 08, 2023

Annual Symposium 2023: Winners and photos

More than 100 participants attended the 21st Annual Norwegian Symposium on Heart Research, hosted by…

Read more
Norheart uses cookies for analytical purposes, content and ads customisation, and to further develop our services.
Accept
Learn more
Show again